

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai MicroPort MedBot (Group) Co., Ltd.

上海微创医疗机器人(集团)股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2252)

VOLUNTARY ANNOUNCEMENT

This announcement is made by Shanghai MicroPort MedBot (Group) Co., Ltd. (the **“Company”**), together with its subsidiaries, the **“Group”**) on a voluntary basis.

The board of directors of the Company (the **“Board”**) hereby informs the shareholders of the Company (the **“Shareholders”**) and potential investors that, based on the preliminary assessment and analysis of the unaudited consolidated management accounts of the Group for the year ended 31 December 2025 (the **“Reporting Period”**) and the data currently available to the Board, the Board expects that the revenue of the Company for the Reporting Period will achieve a year-on-year growth of approximately 110% to 120% as compared to the year ended 31 December 2024. Such significant growth is mainly attributable to that the core product Toumai® Laparoscopic Surgical Robot (**“Toumai”**) has made breakthrough progress in commercialisation and achieved rapid growth in sales. In particular, Toumai has achieved remarkable success in overseas market expansion, with new orders in overseas markets exceeded 100 units over the year, and overseas market sales revenue reaching over five times that of the previous year, which far outpaced the industry average, representing strong momentum for global expansion.

As of the date of this announcement, Toumai has accumulated over 180 commercial orders worldwide, and the commercial installations worldwide of Toumai have exceeded 120 units.

The Board expects that the Group will record an adjusted net loss¹ of not more than RMB240 million for the year ended 31 December 2025, representing a reduction of over 50% as compared to the adjusted net loss of approximately RMB482 million for the year ended 31 December 2024. Such reduction in loss is mainly attributable to (i) the rapid growth in revenue; and (ii) the significant decrease in product costs and operating expenses under various cost reduction and efficiency improvement measures.

Meanwhile, owing to the Group's efficient cash flow management measures, the net free cash outflow² for the year ended 31 December 2025 recorded a significant reduction to no more than RMB70 million, representing a decrease of over 80% as compared to the year ended 31 December 2024.

The figures contained in this announcement represent only the preliminary assessment by the Board with reference to the unaudited consolidated management accounts of the Group and the other information currently available to the Board, which have neither been audited or reviewed by the independent auditor of the Company nor confirmed by the audit committee of the Company. As the Company is still in the process of finalising its financial results for the Reporting Period, the final results for the Reporting Period may be subject to changes and may differ from the figures disclosed in this announcement. The final results of the Company for the Reporting Period and other details of the Group's operations are expected to be disclosed in the annual results announcement of the Company for the Reporting Period to be published before the end of March 2026. Shareholders and potential investors are advised to read the audited annual results announcement carefully after its publication.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Shanghai MicroPort MedBot (Group) Co., Ltd.
Dr. Zhaohua Chang
Chairman

Shanghai, China, 21 January 2026

As at the date of this announcement, the executive directors are Dr. Chao He and Mr. Yu Liu, the non-executive directors are Dr. Zhaohua Chang, Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Mr. Chen Chen and Ms. Min Liang, and the independent non-executive directors are Dr. Guoen Liu, Mr. Jonathan H. Chou, Mr. Haisong Yao and Mr. Wai Man Chung.

¹ The Company uses adjusted net loss as a non-HKFRS measure, which does not take into account the impact on losses attributable to share-based payment expenses, changes in the fair value of financial instruments and impairment losses on equity-accounted investees.

² Free cash flow represents the sum of net cash used in operating activities, net cash used for purchase of property, plant and equipment and intangible assets, and net cash used for payment of lease rentals and deposits.